Túlio Tadeu Rocha Sarmento1, Isabella Piassi Godói2,3, Edna Afonso Reis4, Brian Godman5,6,7,8, Cristina Mariano Ruas9. 1. School of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. 2. SUS Collaborating Centre for Technology Assessment and Excellence in Health, sala 1042, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Presidente Antônio Carlos, 6627, Campus Pampulha, Belo Horizonte, Minas Gerais, CEP, Brazil. 3. College of Public Health, Institute of Health and Biological Studies, Universidade Federal do Sul e Sudeste do Pará, Pará, Brazil. 4. Departament of Statistics, Exact Sciences Institute, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 5. Department of Pharmacoepidemiology, Institute of Pharmacy and Biomedical Sciences, Glasgow, UK. 6. Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden. 7. Health Economics Centre, Liverpool University Management School, Liverpool, UK. 8. School of Pharmacy, Department of Public Health and Pharmacy Management, Sefako Health Sciences University, Pretoria, South Africa. 9. Programa de Pós-Graduação em Medicamentos e Assistência Farmacêutica, School of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Abstract
BACKGROUND: Chikungunya fever is an important infectious disease transmitted by the bite of the mosquitoes. Information about consumers' willingness to pay (WTP) for a hypothetical vaccine can help with future discussions about its possible price. METHODS: A cross-sectional study conducted among residents of Minas Gerais, Brazil, regarding their WTP for a hypothetical chikungunya vaccine defined by the authors as having a mean effective protection of 80%. RESULTS: We interviewed 496 individuals. Among these, 23 were excluded from the analysis. Most of the respondents were female (57.3%), had completed at least high school (90.7%), were employed (87.7%) and had private health insurance (62.6%). The median value of the WTP was US$ 31.17 (120.00 BRL) for a unique dose vaccine. The WTP showed a statistical significant correlation with monthly family income and access to private health insurance. CONCLUSION: This study can contribute to decision-making about potential prices for a chikungunya vaccine once it becomes available in Brazil. We demonstrated the relevance of the anchoring effect as a possible influence applied to the maximum value of the WTP associated with respondents' preference for a new vaccine. Finally, we encourage the development of a chikungunya virus vaccine to benefit the Brazilian population.
BACKGROUND: Chikungunya fever is an important infectious disease transmitted by the bite of the mosquitoes. Information about consumers' willingness to pay (WTP) for a hypothetical vaccine can help with future discussions about its possible price. METHODS: A cross-sectional study conducted among residents of Minas Gerais, Brazil, regarding their WTP for a hypothetical chikungunya vaccine defined by the authors as having a mean effective protection of 80%. RESULTS: We interviewed 496 individuals. Among these, 23 were excluded from the analysis. Most of the respondents were female (57.3%), had completed at least high school (90.7%), were employed (87.7%) and had private health insurance (62.6%). The median value of the WTP was US$ 31.17 (120.00 BRL) for a unique dose vaccine. The WTP showed a statistical significant correlation with monthly family income and access to private health insurance. CONCLUSION: This study can contribute to decision-making about potential prices for a chikungunya vaccine once it becomes available in Brazil. We demonstrated the relevance of the anchoring effect as a possible influence applied to the maximum value of the WTP associated with respondents' preference for a new vaccine. Finally, we encourage the development of a chikungunya virus vaccine to benefit the Brazilian population.
Entities:
Keywords:
Brazil; Willingness to pay; chikungunya; consumers; vaccine